Epithalon vs MOTS-c
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Epithalon or MOTS-c?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Epithalon and MOTS-c?
Epithalon is a synthetic tetrapeptide targeting telomerase; MOTS-c is a mitochondrial-derived peptide targeting AMPK and metabolic regulation - fundamentally different aging pathways.
Evidence Comparison
Epithalon: Khavinson group cohort studies in elderly subjects, no independent replication. MOTS-c: Yang et al. 2016 (Cell Metabolism) discovery paper from the Lee lab, independently replicated metabolic effects in rodents, but no human efficacy data. MOTS-c has better independent validation; epithalon has more (single-group) human exposure data.
Evidence Context Favoring Epithalon
Telomere-focused longevity research where the Khavinson human cohort data is considered acceptable.
Evidence Context Favoring MOTS-c
Metabolic aging research targeting AMPK pathways and insulin sensitivity, where independent lab replication matters.
Side-by-Side Snapshot
| Evidence grade | Epithalon: Level C MOTS-c: Level D |
|---|---|
| Research status | Epithalon: Preclinical MOTS-c: Preclinical |
| Primary category | Epithalon: Anti-Aging & Longevity MOTS-c: Anti-Aging & Longevity |
| Cited studies | Epithalon: 2 MOTS-c: 3 |